Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk
January 25, 2022 09:00 ET
|
Chiesi USA, Inc.
Post hoc analysis of the CHAMPION PHOENIX clinical trial demonstrates that the majority of ischemic events occurred early in percutaneous coronary intervention (PCI), and KENGREAL® (cangrelor)...
Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2022
January 24, 2022 09:00 ET
|
Chiesi USA, Inc.
Chiesi USA celebrates seven consecutive years of recognition from the Top Employers Institute CARY, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of...
A new clinical framework redefines the diagnosis of COPD Exacerbations
December 20, 2021 09:00 ET
|
Chiesi USA, Inc.
The recommendations of an international expert panel to update the definition and severity classification of chronic obstructive pulmonary disease (COPD) exacerbations will be presented by Professor...
Chiesi USA Promotes Polly Petrino to VP, Finance and Member of Leadership Team
November 08, 2021 09:00 ET
|
Chiesi USA, Inc.
Finance leader with more than 20 years of expertise will lead finance, administrative and contracting functions CARY, N.C., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-A-zee), a Cary-based...
Chiesi USA Donates nearly $15,000 to Three Triangle Nonprofits through Partnership with Durham Bulls
October 06, 2021 09:00 ET
|
Chiesi USA, Inc.
Partnership spotlights Triangle nonprofits as the true champions with Chiesi as the 2021 presenting strikeouts sponsor CARY, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- As the Durham Bulls took down...
Chiesi USA Announces Publication of Cost-Consequence Analysis of KENGREAL® (cangrelor) in Cardiac Patients at High Risk of Complications Following PCI in the American Journal of Cardiovascular Drugs
August 10, 2021 09:00 ET
|
Chiesi USA, Inc.
CARY, N.C., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced...
Chiesi accelerates path toward full sustainability despite COVID-19 pandemic
June 23, 2021 09:00 ET
|
Chiesi USA, Inc.
Ensuring continuing medical treatment for patients has been top priority during COVID-19 pandemic.Focus on Diversity & Inclusion in the workplace: 53% of all employees are women – ratio of female...
Chiesi USA announces new organizational leadership for the Chiesi Foundation
May 13, 2021 09:00 ET
|
Chiesi USA, Inc.
Maria Paola Chiesi, former Coordinator of the Foundation since 2010, succeeds Dr. Paolo Chiesi CARY, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi...
Chiesi Group calls for #ActionOverWords in the fight against climate change
May 10, 2021 08:30 ET
|
Chiesi USA, Inc.
Chiesi Group, the largest international pharmaceutical company Certified B Corporation™, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability...
Chiesi Group receives European Marketing Authorization for Trimbow® inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) delivered through NEXThaler, an extrafine formulation fixed triple combination therapy for the treatment of moderate to severe COPD
April 21, 2021 09:00 ET
|
Chiesi USA, Inc.
Chronic obstructive pulmonary disease (COPD) patients for whom a dry powder inhaler device is preferred, can now benefit from an extrafine formulation fixed triple combination therapy containing an...